{"nctId":"NCT03259789","briefTitle":"Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","startDateStruct":{"date":"2017-11-28","type":"ACTUAL"},"conditions":["Type2 Diabetes Mellitus"],"count":351,"armGroups":[{"label":"Bexagliflozin tablets, 20 mg; Double-Blind","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bexagliflozin tablets, 20 mg"]},{"label":"Bexagliflozin tablets, Placebo; Double Blind","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Bexagliflozin tablets, placebo"]},{"label":"Bexagliflozin Tablets, 20 mg; High Glycemic Group","type":"EXPERIMENTAL","interventionNames":["Drug: Bexagliflozin tablets, 20 mg"]}],"interventions":[{"name":"Bexagliflozin tablets, 20 mg","otherNames":["EGT0001442, EGT0001474"]},{"name":"Bexagliflozin tablets, placebo","otherNames":[]},{"name":"Bexagliflozin tablets, 20 mg","otherNames":["EGT0001442, EGT0001474"]}],"eligibilityModule":{"eligibilityCriteria":"The subjects were required to meet the following criteria at the time of enrollment to be eligible for the study:\n\n1. Had been age ≥ 20 years at screening. Women of childbearing potential were required to have tested negative for pregnancy and have agreed to abstinence or contraception for the duration of the study to avoid any possible pregnancy. Females who were surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of menses greater than 12 months) were eligible if they had tested negative for pregnancy at screening.\n2. a) Had a history of T2DM with an HbA1c level of ≥ 7.5% and ≤ 10.5% at screening, or b) Had a history of T2DM with an HbA1c level of \\>10.5% and ≤ 12.0% at screening\n3. Had been prescribed a stable dose of metformin (≥1500 mg per day in the US or ≥ 1000 mg per day in Japan) as their sole anti-diabetic medication\n4. Had a body mass index (BMI) ≤ 45 kg m-2\n5. Had been able to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines\n6. Had no recent changes to their medications for hypertension or hyperlipidemia (if applicable)\n7. Had the ability to regularly self-administer medication, as evidenced by consumption of all, or at worst one less than all, doses of run-in medication prior to randomization\n\nSubjects who met any of the following criteria were to be excluded from the study:\n\n1. Had a diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young\n2. Were pregnant or breastfeeding\n3. Had one or more hemoglobin alleles that affect HbA1c measurement\n4. Had a history of genitourinary tract infection (e.g., UTI, GMI, vaginitis, balanitis) within 6 weeks of screening or a history of ≥ 3 genitourinary infections requiring treatment within 6 months of screening\n5. Had an estimated glomerular filtration rate (eGFR), as calculated by the modification of diet in renal disease study equation (MDRD), \\< 60 mL min-1 per 1.73 m2\n6. Had a sitting systolic blood pressure \\>180 mmHg or a sitting diastolic blood pressure \\> 110 mmHg at screening\n7. Had exposure to hypoglycemic agent(s) other than metformin during the 8 weeks prior to screening\n8. Had a history of illicit drug use or alcohol abuse in the past 2 years\n9. Had a life expectancy \\< 2 years\n10. Had a diagnosis of New York Heart Association (NYHA) Class IV heart failure within 3 months of screening\n11. Had experienced an MI, unstable angina, stroke, or hospitalization for heart failure within 3 months of screening\n12. Had exposure to an investigational drug within 30 days\n13. Had a previous exposure to bexagliflozin or EGT0001474\n14. Had a history of SGLT2 inhibitor treatment\n15. Were participating in another interventional trial\n16. Were not able to comply with the study scheduled visits\n17. Had any condition, disease, disorder, or clinically relevant abnormality that, in the opinion of the primary investigator, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment\n18. Had an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 × ULN or total bilirubin ≥ 1.5 × ULN at screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 24 for Double-blind Group","description":"HbA1c was obtained at baseline and at Week 24. The model-adjusted change from baseline was calculated using mixed-effects repeated measures analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.09","spread":"0.076"},{"groupId":"OG001","value":"-0.56","spread":"0.075"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 24 for High Glycemic Group","description":"The change in HbA1c from baseline at Week 24 in High Glycemic Group was calculated by subtracting the mean HbA1c at baseline from the mean HbA1c at Week 24","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.82","spread":"1.084"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 for Double-blind Group","description":"FPG was obtained at baseline and at Week 24. The model-adjusted change from baseline was calculated using mixed-effects repeated measures analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.51","spread":"0.174"},{"groupId":"OG001","value":"-1.16","spread":"0.173"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 for High Glycemic Group","description":"The change in FPG from baseline at Week 24 for High Glycemic Group was calculated by subtracting the mean FPG at baseline from the mean FPG at Week 24","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.98","spread":"3.437"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure (SBP) at Week 24","description":"Changes from baseline at Week 24 in SBP for the double-blind group and high glycemic group","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.03","spread":"0.993"},{"groupId":"OG001","value":"2.04","spread":"0.987"},{"groupId":"OG002","value":"-8.19","spread":"14.882"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Achieving HbA1c < 7% Over Time for Double-blind Group","description":"The proportion of subjects who achieved HbA1c \\< 7% at 6, 12, 18 and 24 weeks were calculated based on the number of subjects with a value at each time point for each group. The model-adjusted proportion was calculated based on a logistic analysis using Generalized Estimating Equation (GEE) logistic regression that includes country, treatment, visit, treatment-by-visit interaction and the baseline HbA1c value as a fixed effect covariate. An unstructured correlation structure will be used, or autoregressive if the model with the unstructured structure does not converge.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Achieving HbA1c < 7% Over Time for High Glycemic Group","description":"The proportion of subjects who achieved HbA1c \\< 7% at 6, 12, 18 and 24 weeks were calculated based on the number of subjects with a value at each time point for each group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.065","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.097","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.138","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2 for Double-blind Group","description":"Changes in body mass from baseline to week 24 was calculated based on LS means for both bexagliflozin and placebo groups.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.60","spread":"0.348"},{"groupId":"OG001","value":"-1.09","spread":"0.336"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2 for High Glycemic Group","description":"The change in body mass from baseline at week 24 for High Glycemic group was calculated by subtracting the mean body mass at baseline from the mean body mass at week 24","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"3.759"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c Over Time in Double-blind Treatment Group","description":"The change from baseline in HbA1c at 6, 12, 18 and 24 weeks was calculated based on the number of subjects with a value at each time point for each group. The model-adjusted change from baseline was calculated based on a mixed-effects repeated measures analysis that includes country, treatment, visit, treatment-by-visit interaction and the baseline HbA1c value as a fixed effect covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.065"},{"groupId":"OG001","value":"-0.16","spread":"0.065"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"0.073"},{"groupId":"OG001","value":"-0.31","spread":"0.073"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.072"},{"groupId":"OG001","value":"-0.51","spread":"0.072"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.09","spread":"0.076"},{"groupId":"OG001","value":"-0.56","spread":"0.075"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c Over Time Among Subjects Who Have Baseline HbA1c of > 10.5% and ≤ 12.0%","description":"The change from baseline in HbA1c at 6, 12, 18 and 24 weeks was calculated based on the number of subjects with a value at each time point in High Glycemic Group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.72","spread":"1.027"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.45","spread":"1.136"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.62","spread":"1.055"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.82","spread":"1.084"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":158},"commonTop":["Nasopharyngitis","Polyuria","Diabetes mellitus inadequate control","Polydipsia","Glomerular filtration rate decreased"]}}}